Emerging from hepatitis B flops, Assembly Bio showcases early data on next-gen drugs

Amber Tong

John McHutchison will be leaving Assembly Biosciences with a glimpse at the future he promised after the biotech ran into multiple setbacks in its pursuit …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Emerging from hepatitis B flops, Assembly Bio showcases early data on next-gen drugs

Amber Tong

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA approves first drug to treat ultra-rare lipid storage disease

FDA says Ozempic, Wegovy shortage is over

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Emerg­ing from he­pati­tis B flops, As­sem­bly Bio show­cas­es ear­ly da­ta on next-gen drugs

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Emerging from hepatitis B flops, Assembly Bio showcases early data on next-gen drugs